These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

366 related items for PubMed ID: 17283150

  • 1. Insulin-like growth factor-I receptor signaling blockade combined with radiation.
    Allen GW, Saba C, Armstrong EA, Huang SM, Benavente S, Ludwig DL, Hicklin DJ, Harari PM.
    Cancer Res; 2007 Feb 01; 67(3):1155-62. PubMed ID: 17283150
    [Abstract] [Full Text] [Related]

  • 2. Growth-inhibitory effects of human anti-insulin-like growth factor-I receptor antibody (A12) in an orthotopic nude mouse model of anaplastic thyroid carcinoma.
    Wang Z, Chakravarty G, Kim S, Yazici YD, Younes MN, Jasser SA, Santillan AA, Bucana CD, El-Naggar AK, Myers JN.
    Clin Cancer Res; 2006 Aug 01; 12(15):4755-65. PubMed ID: 16899627
    [Abstract] [Full Text] [Related]

  • 3. A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo.
    Burtrum D, Zhu Z, Lu D, Anderson DM, Prewett M, Pereira DS, Bassi R, Abdullah R, Hooper AT, Koo H, Jimenez X, Johnson D, Apblett R, Kussie P, Bohlen P, Witte L, Hicklin DJ, Ludwig DL.
    Cancer Res; 2003 Dec 15; 63(24):8912-21. PubMed ID: 14695208
    [Abstract] [Full Text] [Related]

  • 4. Selective inhibition of SCLC growth by the A12 anti-IGF-1R monoclonal antibody correlates with inhibition of Akt.
    Yeh J, Litz J, Hauck P, Ludwig DL, Krystal GW.
    Lung Cancer; 2008 May 15; 60(2):166-74. PubMed ID: 18006183
    [Abstract] [Full Text] [Related]

  • 5. IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptor.
    Rowinsky EK, Youssoufian H, Tonra JR, Solomon P, Burtrum D, Ludwig DL.
    Clin Cancer Res; 2007 Sep 15; 13(18 Pt 2):5549s-5555s. PubMed ID: 17875788
    [Abstract] [Full Text] [Related]

  • 6. A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I.
    Sachdev D, Li SL, Hartell JS, Fujita-Yamaguchi Y, Miller JS, Yee D.
    Cancer Res; 2003 Feb 01; 63(3):627-35. PubMed ID: 12566306
    [Abstract] [Full Text] [Related]

  • 7. Insulin-like growth factor receptor as a therapeutic target in head and neck cancer.
    Barnes CJ, Ohshiro K, Rayala SK, El-Naggar AK, Kumar R.
    Clin Cancer Res; 2007 Jul 15; 13(14):4291-9. PubMed ID: 17634559
    [Abstract] [Full Text] [Related]

  • 8. [shRNA-mediated insulin-like growth factor I receptor gene silencing inhibits cell proliferation, induces cell apoptosis, and suppresses tumor growth in non-small cell lung cancer: in vitro and in vivo experiments].
    Dong AQ, Kong MJ, Ma ZY, Qian JF, Fan JQ, Xu XH.
    Zhonghua Yi Xue Za Zhi; 2007 Jun 05; 87(21):1506-9. PubMed ID: 17785094
    [Abstract] [Full Text] [Related]

  • 9. Differential mechanisms of acquired resistance to insulin-like growth factor-i receptor antibody therapy or to a small-molecule inhibitor, BMS-754807, in a human rhabdomyosarcoma model.
    Huang F, Hurlburt W, Greer A, Reeves KA, Hillerman S, Chang H, Fargnoli J, Graf Finckenstein F, Gottardis MM, Carboni JM.
    Cancer Res; 2010 Sep 15; 70(18):7221-31. PubMed ID: 20807811
    [Abstract] [Full Text] [Related]

  • 10. RAV12 accelerates the desensitization of Akt/PKB pathway of insulin-like growth factor I receptor signaling in COLO205.
    Li JC, Li R.
    Cancer Res; 2007 Sep 15; 67(18):8856-64. PubMed ID: 17875727
    [Abstract] [Full Text] [Related]

  • 11. In vitro and in vivo antitumor effects of the dual insulin-like growth factor-I/insulin receptor inhibitor, BMS-554417.
    Haluska P, Carboni JM, Loegering DA, Lee FY, Wittman M, Saulnier MG, Frennesson DB, Kalli KR, Conover CA, Attar RM, Kaufmann SH, Gottardis M, Erlichman C.
    Cancer Res; 2006 Jan 01; 66(1):362-71. PubMed ID: 16397250
    [Abstract] [Full Text] [Related]

  • 12. Down-regulation of insulin-like growth factor I receptor activity by NVP-AEW541 has an antitumor effect on neuroblastoma cells in vitro and in vivo.
    Tanno B, Mancini C, Vitali R, Mancuso M, McDowell HP, Dominici C, Raschellà G.
    Clin Cancer Res; 2006 Nov 15; 12(22):6772-80. PubMed ID: 17121898
    [Abstract] [Full Text] [Related]

  • 13. Genetic blockade of the insulin-like growth factor-I receptor: a promising strategy for human pancreatic cancer.
    Min Y, Adachi Y, Yamamoto H, Ito H, Itoh F, Lee CT, Nadaf S, Carbone DP, Imai K.
    Cancer Res; 2003 Oct 01; 63(19):6432-41. PubMed ID: 14559833
    [Abstract] [Full Text] [Related]

  • 14. Inhibition of in vivo breast cancer growth by antisense oligodeoxynucleotides to type I insulin-like growth factor receptor mRNA involves inactivation of ErbBs, PI-3K/Akt and p42/p44 MAPK signaling pathways but not modulation of progesterone receptor activity.
    Salatino M, Schillaci R, Proietti CJ, Carnevale R, Frahm I, Molinolo AA, Iribarren A, Charreau EH, Elizalde PV.
    Oncogene; 2004 Jul 01; 23(30):5161-74. PubMed ID: 15122317
    [Abstract] [Full Text] [Related]

  • 15. An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation.
    Maloney EK, McLaughlin JL, Dagdigian NE, Garrett LM, Connors KM, Zhou XM, Blättler WA, Chittenden T, Singh R.
    Cancer Res; 2003 Aug 15; 63(16):5073-83. PubMed ID: 12941837
    [Abstract] [Full Text] [Related]

  • 16. Down-regulation of insulin receptor by antibodies against the type I insulin-like growth factor receptor: implications for anti-insulin-like growth factor therapy in breast cancer.
    Sachdev D, Singh R, Fujita-Yamaguchi Y, Yee D.
    Cancer Res; 2006 Feb 15; 66(4):2391-402. PubMed ID: 16489046
    [Abstract] [Full Text] [Related]

  • 17. Insulin-like growth factor receptor I targeting in epithelial ovarian cancer.
    Gotlieb WH, Bruchim I, Gu J, Shi Y, Camirand A, Blouin MJ, Zhao Y, Pollak MN.
    Gynecol Oncol; 2006 Feb 15; 100(2):389-96. PubMed ID: 16300820
    [Abstract] [Full Text] [Related]

  • 18. Insulin-like growth factor-I receptor blockade reduces the invasiveness of gastrointestinal cancers via blocking production of matrilysin.
    Adachi Y, Li R, Yamamoto H, Min Y, Piao W, Wang Y, Imsumran A, Li H, Arimura Y, Lee CT, Imai K, Carbone DP, Shinomura Y.
    Carcinogenesis; 2009 Aug 15; 30(8):1305-13. PubMed ID: 19493905
    [Abstract] [Full Text] [Related]

  • 19. Recombinant human insulin-like growth factor binding protein 3 inhibits growth of human epidermal growth factor receptor-2-overexpressing breast tumors and potentiates herceptin activity in vivo.
    Jerome L, Alami N, Belanger S, Page V, Yu Q, Paterson J, Shiry L, Pegram M, Leyland-Jones B.
    Cancer Res; 2006 Jul 15; 66(14):7245-52. PubMed ID: 16849573
    [Abstract] [Full Text] [Related]

  • 20. Growth inhibition of insulin-like growth factor I receptor monoclonal antibody to human colorectal cancer cells.
    Zhang Y, Zhang Y.
    Cancer Invest; 2008 Jul 15; 26(3):230-6. PubMed ID: 18317963
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.